Bortezomib/Thalidomide/Dexamethasone (VTD) Is Superior to Bortezomib/Cyclophosphamide/ Dexamethasone (VCD) Prior to ASCT for Patients with De Novo MM
Researchers presented results of the randomized, prospective IFM 2013-04 trial that compared the induction treatment regimens of bortezomib/thalidomide/dexamethasone and bortezomib/cyclophosphamide/dexamethasone prior to autologous stem-cell transplant (ASCT) in patients with de novo multiple myeloma (MM).
Factors Influencing Second-Line Treatment with Triplet Therapy for Patients with RRMM in Routine Care
In this study, the clinical value of minimal residual disease (MRD) status in achieving prolonged remissions was assessed in patients with multiple myeloma (MM) who had achieved at least very good partial response or complete response at 4 to 8 months and 12 to 24 months, or long-term relapse-free survivors (>6 years).
A randomized phase 2 study evaluated the safety and antimyeloma activity of 2 different doses of ixazomib (4 mg or 5.5 mg weekly for 3 weeks with a week off) plus dexamethasone (40 mg weekly) in patients with relapsed multiple myeloma (MM) but who were not refractory to bortezomib; results of this study were reported at the meeting.
Researchers presented updated results of the randomized phase 3 ELOQUENT-2 study that evaluated the anti-SLAM7 monoclonal antibody elotuzumab plus lenalidomide/dexamethasone versus lenalidomide/dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM).
Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study.
ISS Staging May Be Inadequate in Classifying All Patients with Newly Diagnosed MM by Disease and Symptom Burden
This study analyzed data from the longitudinal CoMMpass trial led by the Multiple Myeloma Research Foundation to determine the degree to which the International Staging System (ISS) stage was associated with disease and symptom burden in patients with newly diagnosed multiple myeloma (MM).
Bortezomib-Based Induction and Maintenance Therapy Results in Durable Survival Improvements in Newly Diagnosed MM Patients
Researchers reported long-term follow-up results of the HOVON-65/GMMG-HD4 trial that evaluated survival outcomes with bortezomib-based induction and maintenance regimens followed by high-dose melphalan and autologous stem-cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma (MM) compared with the standard regimen. The impact of the bortezomib-based regimen on survival in the high-risk cytogenetic and renally impaired subset of patients was also reported.
Page 24 of 27
Results 231 - 240 of 261
Results 231 - 240 of 261